David McDonnell

1.9k total citations
68 papers, 1.3k citations indexed

About

David McDonnell is a scholar working on Psychiatry and Mental health, Pharmacology and Philosophy. According to data from OpenAlex, David McDonnell has authored 68 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Psychiatry and Mental health, 29 papers in Pharmacology and 8 papers in Philosophy. Recurrent topics in David McDonnell's work include Schizophrenia research and treatment (56 papers), Treatment of Major Depression (29 papers) and Bipolar Disorder and Treatment (25 papers). David McDonnell is often cited by papers focused on Schizophrenia research and treatment (56 papers), Treatment of Major Depression (29 papers) and Bipolar Disorder and Treatment (25 papers). David McDonnell collaborates with scholars based in United States, Ireland and Germany. David McDonnell's co-authors include Holland C. Detke, Daniel Lin, Richard F. Bergstrom, Adam Simmons, Ying Jiang, Fangyi Zhao, Lei Sun, John M. Kane, Lauren DiPetrillo and Lisa Von Moltke and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and The British Journal of Psychiatry.

In The Last Decade

David McDonnell

65 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David McDonnell United States 19 1.1k 374 213 153 123 68 1.3k
Michelle Kramer United States 15 1.6k 1.4× 283 0.8× 254 1.2× 181 1.2× 147 1.2× 27 1.9k
Dan Zimbroff United States 12 890 0.8× 266 0.7× 317 1.5× 125 0.8× 134 1.1× 21 1.3k
Maju Mathews United States 18 702 0.6× 300 0.8× 204 1.0× 99 0.6× 76 0.6× 73 1.0k
Mary Anne Dellva United States 16 831 0.7× 236 0.6× 185 0.9× 171 1.1× 106 0.9× 44 1.3k
Keith Karcher United States 17 1.2k 1.1× 214 0.6× 264 1.2× 244 1.6× 179 1.5× 27 1.5k
P.V. Tran United States 7 938 0.8× 258 0.7× 174 0.8× 230 1.5× 117 1.0× 15 1.2k
Heike Hunger Germany 13 1.5k 1.3× 273 0.7× 282 1.3× 245 1.6× 163 1.3× 14 1.9k
Taro Iwamoto United States 10 1.2k 1.1× 162 0.4× 265 1.2× 79 0.5× 136 1.1× 14 1.4k
R. Tamura United States 8 865 0.8× 236 0.6× 173 0.8× 203 1.3× 109 0.9× 30 1.1k
Joris Berwaerts United States 23 880 0.8× 212 0.6× 119 0.6× 84 0.5× 200 1.6× 49 1.4k

Countries citing papers authored by David McDonnell

Since Specialization
Citations

This map shows the geographic impact of David McDonnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David McDonnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David McDonnell more than expected).

Fields of papers citing papers by David McDonnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David McDonnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David McDonnell. The network helps show where David McDonnell may publish in the future.

Co-authorship network of co-authors of David McDonnell

This figure shows the co-authorship network connecting the top 25 collaborators of David McDonnell. A scholar is included among the top collaborators of David McDonnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David McDonnell. David McDonnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Citrome, Leslie, Christoph U. Correll, Andrew J. Cutler, et al.. (2025). Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia. Neuropsychiatric Disease and Treatment. Volume 21. 575–596. 2 indexed citations
2.
Simmons, Adam, et al.. (2024). Using qualitative exit interviews to explore schizophrenia burden and treatment experience in clinical trial patients. Frontiers in Psychiatry. 15. 1377174–1377174. 2 indexed citations
3.
Correll, Christoph U., Michael J. Doane, David McDonnell, Sarah Akerman, & Stephen R. Saklad. (2024). Olanzapine/Samidorphan Effects on Weight Gain. The Journal of Clinical Psychiatry. 86(1).
4.
Kahn, René S., John M. Kane, Christoph U. Correll, et al.. (2023). Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness. The Journal of Clinical Psychiatry. 84(3). 12 indexed citations
5.
Matthews, Thomas P., et al.. (2023). The Leaking Ear: A Billiard Ball Sized Otogenic Acute Brain Abscess. European Journal of Case Reports in Internal Medicine. 10(4). 3774–3774.
6.
Correll, Christoph U., Mikkel Højlund, Christine Graham, et al.. (2023). Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis. The International Journal of Neuropsychopharmacology. 26(7). 451–464. 11 indexed citations
7.
Doane, Michael J., Leona Bessonova, Kevin Mortimer, et al.. (2022). Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry. 22(1). 114–114. 17 indexed citations
8.
Toledo, Frederico G. S., William Martin, Linda Morrow, et al.. (2021). Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers. Neuropsychopharmacology. 47(3). 696–703. 8 indexed citations
9.
Citrome, Leslie, Christine Graham, Adam Simmons, et al.. (2021). An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder. Neuropsychiatric Disease and Treatment. Volume 17. 2885–2904. 17 indexed citations
10.
Potkin, Steven G., Jelena Kunovac, Bernard L. Silverman, et al.. (2020). Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia. The Journal of Clinical Psychiatry. 81(2). 47 indexed citations
11.
Brunette, Mary F., Christoph U. Correll, David McDonnell, et al.. (2020). Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder. The Journal of Clinical Psychiatry. 81(2). 18 indexed citations
12.
Sun, Lei, David McDonnell, & Lisa Von Moltke. (2018). Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia. Clinical Therapeutics. 40(11). 1845–1854.e2. 31 indexed citations
13.
McDonnell, David, et al.. (2017). Eosinophilic myocarditis as a first presentation of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). BMJ Case Reports. 2017. bcr–2017. 9 indexed citations
14.
15.
16.
McDonnell, David, John Landry, & Holland C. Detke. (2014). Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology. 29(6). 322–331. 22 indexed citations
17.
18.
Detke, Holland C., David McDonnell, Eric J. Brunner, et al.. (2010). Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 10(1). 43–43. 82 indexed citations
19.
Ahn, Jeonghoon, Jeffrey S. McCombs, Tim Croudace, et al.. (2007). Classifying Patients by Antipsychotic Adherence Patterns Using Latent Class Analysis: Characteristics of Nonadherent Groups in the California Medicaid (Medi-Cal) Program. Value in Health. 11(1). 48–56. 56 indexed citations
20.
Mamo, David C., Shitij Kapur, Matcheri S. Keshavan, et al.. (2007). D2 Receptor Occupancy of Olanzapine Pamoate Depot Using Positron Emission Tomography: An Open-label Study in Patients with Schizophrenia. Neuropsychopharmacology. 33(2). 298–304. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle Kramer Breakdown of academic impact, for papers by Dan Zimbroff Breakdown of academic impact, for papers by Maju Mathews Breakdown of academic impact, for papers by Mary Anne Dellva Breakdown of academic impact, for papers by Keith Karcher Breakdown of academic impact, for papers by P.V. Tran Breakdown of academic impact, for papers by Heike Hunger Breakdown of academic impact, for papers by Taro Iwamoto Breakdown of academic impact, for papers by R. Tamura Breakdown of academic impact, for papers by Joris Berwaerts
Rankless by CCL
2026